These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 31066242)

  • 1. Inhibition of myostatin improves muscle atrophy in oculopharyngeal muscular dystrophy (OPMD).
    Harish P; Malerba A; Lu-Nguyen N; Forrest L; Cappellari O; Roth F; Trollet C; Popplewell L; Dickson G
    J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1016-1026. PubMed ID: 31066242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Myostatin Reduces Collagen Deposition in a Mouse Model of Oculopharyngeal Muscular Dystrophy (OPMD) With Established Disease.
    Harish P; Forrest L; Herath S; Dickson G; Malerba A; Popplewell L
    Front Physiol; 2020; 11():184. PubMed ID: 32194441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic Delivery of a Monoclonal Antibody to Immunologically Block Myostatin in the A17 Mouse Model of OPMD.
    Malerba A; Harish P; Popplewell L
    Methods Mol Biol; 2023; 2587():557-568. PubMed ID: 36401050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and phenotypic characterization of a mouse model of oculopharyngeal muscular dystrophy reveals severe muscular atrophy restricted to fast glycolytic fibres.
    Trollet C; Anvar SY; Venema A; Hargreaves IP; Foster K; Vignaud A; Ferry A; Negroni E; Hourde C; Baraibar MA; 't Hoen PA; Davies JE; Rubinsztein DC; Heales SJ; Mouly V; van der Maarel SM; Butler-Browne G; Raz V; Dickson G
    Hum Mol Genet; 2010 Jun; 19(11):2191-207. PubMed ID: 20207626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear entrapment and extracellular depletion of PCOLCE is associated with muscle degeneration in oculopharyngeal muscular dystrophy.
    Raz V; Sterrenburg E; Routledge S; Venema A; van der Sluijs BM; Trollet C; Dickson G; van Engelen BG; van der Maarel SM; Antoniou MN
    BMC Neurol; 2013 Jul; 13():70. PubMed ID: 23815790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atrophy, fibrosis, and increased PAX7-positive cells in pharyngeal muscles of oculopharyngeal muscular dystrophy patients.
    Gidaro T; Negroni E; Perié S; Mirabella M; Lainé J; Lacau St Guily J; Butler-Browne G; Mouly V; Trollet C
    J Neuropathol Exp Neurol; 2013 Mar; 72(3):234-43. PubMed ID: 23399899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice.
    Murphy KT; Chee A; Gleeson BG; Naim T; Swiderski K; Koopman R; Lynch GS
    Am J Physiol Regul Integr Comp Physiol; 2011 Sep; 301(3):R716-26. PubMed ID: 21677277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
    St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
    Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of the ubiquitin-proteasome system contributes to oculopharyngeal muscular dystrophy through muscle atrophy.
    Ribot C; Soler C; Chartier A; Al Hayek S; Naït-Saïdi R; Barbezier N; Coux O; Simonelig M
    PLoS Genet; 2022 Jan; 18(1):e1010015. PubMed ID: 35025870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute antibody-directed myostatin inhibition attenuates disuse muscle atrophy and weakness in mice.
    Murphy KT; Cobani V; Ryall JG; Ibebunjo C; Lynch GS
    J Appl Physiol (1985); 2011 Apr; 110(4):1065-72. PubMed ID: 21270350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Established PABPN1 intranuclear inclusions in OPMD muscle can be efficiently reversed by AAV-mediated knockdown and replacement of mutant expanded PABPN1.
    Malerba A; Klein P; Lu-Nguyen N; Cappellari O; Strings-Ufombah V; Harbaran S; Roelvink P; Suhy D; Trollet C; Dickson G
    Hum Mol Genet; 2019 Oct; 28(19):3301-3308. PubMed ID: 31294444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different outcomes of endurance and resistance exercise in skeletal muscles of Oculopharyngeal muscular dystrophy.
    Boulinguiez A; Dhiab J; Crisol B; Muraine L; Gaut L; Rouxel C; Flaire J; Mouigni HR; Lemaitre M; Giroux B; Audoux L; SaintPierre B; Ferry A; Mouly V; Butler-Browne G; Negroni E; Malerba A; Trollet C
    J Cachexia Sarcopenia Muscle; 2024 Aug; ():. PubMed ID: 39113268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranuclear Aggregates Precede Clinical Onset in Oculopharyngeal Muscular Dystrophy.
    van der Sluijs BM; Raz V; Lammens M; van den Heuvel LP; Voermans NC; van Engelen BG
    J Neuromuscul Dis; 2016 Mar; 3(1):101-109. PubMed ID: 27854203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Over-expression of BCL2 rescues muscle weakness in a mouse model of oculopharyngeal muscular dystrophy.
    Davies JE; Rubinsztein DC
    Hum Mol Genet; 2011 Mar; 20(6):1154-63. PubMed ID: 21199860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-Associated Salivary MicroRNA Biomarkers for Oculopharyngeal Muscular Dystrophy.
    Raz V; Kroon RHMJM; Mei H; Riaz M; Buermans H; Lassche S; Horlings C; Swart B; Kalf J; Harish P; Vissing J; Kielbasa S; van Engelen BGM
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32842713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oculopharyngeal muscular dystrophy: recent advances in the understanding of the molecular pathogenic mechanisms and treatment strategies.
    Abu-Baker A; Rouleau GA
    Biochim Biophys Acta; 2007 Feb; 1772(2):173-85. PubMed ID: 17110089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel mouse models of oculopharyngeal muscular dystrophy (OPMD) reveal early onset mitochondrial defects and suggest loss of PABPN1 may contribute to pathology.
    Vest KE; Phillips BL; Banerjee A; Apponi LH; Dammer EB; Xu W; Zheng D; Yu J; Tian B; Pavlath GK; Corbett AH
    Hum Mol Genet; 2017 Sep; 26(17):3235-3252. PubMed ID: 28575395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological scaffold-mediated delivery of myostatin inhibitor promotes a regenerative immune response in an animal model of Duchenne muscular dystrophy.
    Estrellas KM; Chung L; Cheu LA; Sadtler K; Majumdar S; Mula J; Wolf MT; Elisseeff JH; Wagner KR
    J Biol Chem; 2018 Oct; 293(40):15594-15605. PubMed ID: 30139748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of insoluble PABPN1 accumulation in the diagnosis of oculopharyngeal muscular dystrophy.
    Galimberti V; Tironi R; Lerario A; Scali M; Del Bo R; Rodolico C; Brizzi T; Gibertini S; Maggi L; Mora M; Toscano A; Comi GP; Sciacco M; Moggio M; Peverelli L
    Eur J Neurol; 2020 Apr; 27(4):709-715. PubMed ID: 31769567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Premature proliferative arrest of cricopharyngeal myoblasts in oculo-pharyngeal muscular dystrophy: Therapeutic perspectives of autologous myoblast transplantation.
    Périé S; Mamchaoui K; Mouly V; Blot S; Bouazza B; Thornell LE; St Guily JL; Butler-Browne G
    Neuromuscul Disord; 2006 Nov; 16(11):770-81. PubMed ID: 17005403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.